Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmaron Beijing CoPHBBF 84 Earnings Yield (Joel Greenblatt) % is 3.81% as of Jun. 2026, which is 51% above its 10-year median of 2.53. GuruFocus rates PHBBF with a GF Score™ of 84/100 and a GF Value™ of $1.52. The stock has 4 warning signs investors should review. Among 1,341 Biotechnology companies, Pharmaron Beijing Co ranks better than 86.06% on this metric.
Pharmaron Beijing Co's Enterprise Value for the quarter that ended in Jun. 2026 was $4,314 Mil.
Pharmaron Beijing Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $320 Mil. Pharmaron Beijing Co's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 3.81%.
The historical rank and industry rank for Pharmaron Beijing Co's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
PHBBF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 0.85 Med: 2.53 Max: 6.46
Current: 2.9
During the past 12 years, the highest Earnings Yield (Joel Greenblatt) of Pharmaron Beijing Co was 6.46%. The lowest was 0.85%. And the median was 2.53%.
PHBBF's Earnings Yield (Joel Greenblatt) % is ranked better than 86.06% of 1341
companies
in the Biotechnology industry
Industry Median: -10.09
vs PHBBF: 2.90
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Pharmaron Beijing Co's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 4.85%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Pharmaron Beijing Co (OTCPK:PHBBF) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Pharmaron Beijing Co Earnings Yield (Joel Greenblatt) % Related Terms
Pharmaron Beijing Co Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Pharmaron Beijing Co's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmaron Beijing Co Earnings Yield (Joel Greenblatt) % Chart
For the Biotechnology subindustry, Pharmaron Beijing Co's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaron Beijing Co Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Pharmaron Beijing Co's Earnings Yield (Joel Greenblatt) % falls into.
Pharmaron Beijing Co Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Pharmaron Beijing Cos Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Pharmaron Beijing Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $320 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 3.81% mean?
Pharmaron Beijing Co (PHBBF) has a Earnings Yield (Joel Greenblatt) % of 3.81% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Pharmaron Beijing Co and its competitors. This is 51% above median its historical median of 2.53. Over the past decade, Pharmaron Beijing Co's Earnings Yield (Joel Greenblatt) % has ranged from 0.85 to 6.46. According to the industry distribution chart, Pharmaron Beijing Co ranks #187 out of 1341 companies in the Biotechnology industry, placing it in the top 13.9%.
Is Pharmaron Beijing Co's Earnings Yield (Joel Greenblatt) % too high?
Pharmaron Beijing Co's current Earnings Yield (Joel Greenblatt) % of 3.81% is 51% above median its 10-year median of 2.53. Over the past 10 years, this metric has ranged from a low of 0.85 to a high of 6.46. Based on the distribution chart, Pharmaron Beijing Co ranks #187 out of 1341 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharmaron Beijing Co has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's Earnings Yield (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmaron Beijing Co ranks #187 out of 1341 companies for Earnings Yield (Joel Greenblatt) %. This places Pharmaron Beijing Co in the top 14% of its industry — outperforming the majority of peers. Historically, Pharmaron Beijing Co's own Earnings Yield (Joel Greenblatt) % has ranged from 0.85 to 6.46 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Pharmaron Beijing Co and its competitors. Pharmaron Beijing Co's current Earnings Yield (Joel Greenblatt) % is 3.81%, which is 51% above median its own 10-year median of 2.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Pharmaron Beijing Co (PHBBF) has a current Earnings Yield (Joel Greenblatt) % of 3.81%. The stock's GF Value™ is $1.52, compared to a current price of $1.93 — trading 27% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 3.81%, which is 51% above median its 10-year median of 2.53. Pharmaron Beijing Co's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Pharmaron Beijing Co (PHBBF), the current Earnings Yield (Joel Greenblatt) % is 3.81% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaron Beijing Co (PHBBF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued.
The current stock price of $1.93 is trading 27% above its estimated GF Value™ of $1.52.
Key valuation signals for PHBBF:
Earnings Yield (Joel Greenblatt) %: 3.81% (51% above median its 10-year median of 2.53)
GF Value™: $1.52 vs. price of $1.93 (27% above fair value)
No single metric tells the full story. See the PHBBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
84GF Score
Get the complete analysis for PHBBF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHBBF has been successfully added to your 
